UBS keeps EUR 260 target for Sartorius Stedim stock
Published on 10/21/2026 at 10:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst views and reporting dates
- UBS maintained a Buy rating and EUR 260 target on October 15, 2026.
- AlphaValue raised its target from EUR 238 to EUR 253 on October 8, 2026.
- Sartorius Stedim stock traded at EUR 215.00 at 10:14 a.m. CEST at Lang & Schwarz on October 21, 2026.
Sartorius Stedim stock (ISIN FR0013154002) was trading at EUR 215.00 at Lang & Schwarz on October 21, 2026 at 10:14 a.m. CEST. On October 15, UBS maintained a Buy rating and an EUR 260 target, according to MarketScreener. The next test is the company's third-quarter report.
Analyst targets moved higher
AlphaValue confirmed its Accumulate recommendation and raised its target from EUR 238 to EUR 253 on October 8, 2026. The note cited consumables-led growth, recovering equipment demand, improved free cash flow and deleveraging, while also lowering earnings-per-share forecasts below EBITDA, MarketScreener reported.
What does the recovery mean?
The operating framework remains measurable. Sartorius Stedim reported EUR 1.53 billion of revenue and EUR 463.70 million of EBITDA in the first half of 2026, with an EBITDA margin of 31.40 percent, according to Ideal Investisseur. The company expects 2026 constant-currency revenue growth of 6 to 10 percent and an underlying EBITDA margin slightly above 31 percent, as stated on its Sartorius Stedim Biotech investor-relations page.
Three target changes
RBC set a EUR 220 target on October 6, 2026, according to MarketScreener. AlphaValue then moved from EUR 238 to EUR 253 on October 8, followed by UBS keeping EUR 260 on October 15. The sequence puts the latest UBS target EUR 45.00 above the Lang & Schwarz price, a 20.93 percent difference calculated against EUR 215.00.
Dates for the next release
Sartorius Stedim is scheduled to publish its third-quarter 2026 results on October 22, 2026, while its results conference call is set for the same date at 1:00 p.m. CEST, according to the investor-relations calendar.
Price and valuation
The stock's market capitalization was EUR 20.9 billion as of October 21, 2026, while its 52-week range was EUR 150.00 to EUR 225.00. Sartorius Stedim was trading at EUR 215.00 at Lang & Schwarz on October 21, 2026 at 10:14 a.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of Sartorius Stedim stock.
Sartorius Stedim Biotech at a glance
- Company: Sartorius Stedim Biotech S.A.
- ISIN: FR0013154002
- Ticker: DIM
- Primary exchange: Euronext Paris
- Price Lang & Schwarz (as of October 21, 2026, 10:14 a.m. CEST): EUR 215.00
- Market capitalization: EUR 20.9 billion (as of October 21, 2026)
- 52-week range: EUR 150.00-EUR 225.00 (as of October 21, 2026)
- Sector / Industry: Healthcare / Medical Instruments and Supplies
Market context: Market report CAC 40.
